International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.

التفاصيل البيبلوغرافية
العنوان:	International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.
المؤلفون:	Rotz SJ; Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. rotzs@ccf.org.; Blood and Marrow Transplant Program, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. rotzs@ccf.org., Bhatt NS; Fred Hutchinson Cancer Center, Seattle, WA, USA., Hamilton BK; Blood and Marrow Transplant Program, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Duncan C; Dana Farber/Boston Children's Cancer and Blood Disorders Center, Harvard University, Boston, MA, USA., Aljurf M; King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia., Atsuta Y; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan., Beebe K; Phoenix Children's Hospital and Mayo Clinic Arizona, Phoenix, AZ, USA., Buchbinder D; Division of Hematology, Children's Hospital of Orange County, Orange, CA, USA., Burkhard P; National Bone Marrow Transplant Link, Southfield, MI, USA., Carpenter PA; Fred Hutchinson Cancer Center, Seattle, WA, USA., Chaudhri N; King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia., Elemary M; Hematology and BMT, University of Saskatchewan, Saskatoon, SK, Canada., Elsawy M; Division of Hematology, Dalhousie University, Halifax, NS, Canada.; QEII Health Sciences Center, Halifax, NS, Canada., Guilcher GMT; Section of Pediatric Oncology/Transplant and Cellular Therapy, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Hamad N; Department of Haematology, St Vincent's Hospital Sydney, Sydney, NSW, Australia.; St Vincent's Clinical School Sydney, University of New South Wales, Sydney, NSW, Australia.; School of Medicine Sydney, University of Notre Dame Australia, Sydney, WA, Australia., Karduss A; Bone Marrow Transplant Program, Clinica las Americas, Medellin, Colombia., Peric Z; BMT Unit, Department of Hematology, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia., Purtill D; Fiona Stanley Hospital, Murdoch, WA, Australia.; PathWest Laboratory Medicine, Nedlands, WA, Australia., Rizzo D; Medical College of Wisconsin, Milwaukee, WI, USA.; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Rodrigues M; Israelita Albert Einstein Hospital, São Paulo, Brazil., Ostriz MBR; Division of hematology and bone marrow transplantation, Instituto de trasplante y alta complejidad (ITAC), Buenos Aires, Argentina., Salooja N; Centre for Haematology, Imperial College London, London, UK., Schoemans H; Department of Hematology, University Hospitals Leuven, Leuven, Belgium.; Department of Public Health and Primary Care, ACCENT VV, KU Leuven-University of Leuven, Leuven, Belgium., Seber A; Hospital Samaritano, Sao Paulo, Brazil., Sharma A; Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA., Srivastava A; Department of Haematology, Christian Medical College, Vellore, India., Stewart SK; Blood & Marrow Transplant Information Network, Highland Park, IL, 60035, USA., Baker KS; Fred Hutchinson Cancer Center, Seattle, WA, USA., Majhail NS; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN, USA., Phelan R; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
المصدر:	Bone marrow transplantation [Bone Marrow Transplant] 2024 Jun; Vol. 59 (6), pp. 717-741. Date of Electronic Publication: 2024 Feb 27.
نوع المنشور:	Journal Article; Review
اللغة:	English
بيانات الدورية:	Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
أسماء مطبوعة:	Publication: <2003->: London : Nature Publishing Group Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986-
مواضيع طبية MeSH:	Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods, Humans ; Graft vs Host Disease/prevention & control ; Graft vs Host Disease/etiology ; Survivors ; Adult ; Practice Guidelines as Topic ; Male ; Child
مستخلص:	As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the volume of HCT performed annually continues to rise. Parallel improvements in HCT techniques and supportive care entails more patients surviving long-term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and other underlying risk-factors. Guidelines for screening and preventive practices for HCT survivors were originally published in 2006 and updated in 2012. To review contemporary literature and update the recommendations while considering the changing practice of HCT and cellular therapy, an international group of experts was again convened. This review provides updated pediatric and adult survivorship guidelines for HCT and cellular therapy. The contributory role of chronic graft-versus-host disease (cGVHD) to the development of late effects is discussed but cGVHD management is not covered in detail. These guidelines emphasize special needs of patients with distinct underlying HCT indications or comorbidities (e.g., hemoglobinopathies, older adults) but do not replace more detailed group, disease, or condition specific guidelines. Although these recommendations should be applicable to the vast majority of HCT recipients, resource constraints may limit their implementation in some settings. (© 2024. The Author(s).)
References:	Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. Hematol Oncol Stem Cell Ther. 2020;13:7–16. (PMID: 3144978110.1016/j.hemonc.2019.08.002) Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651–64. (PMID: 10.1038/s41409-021-01227-8) D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transpl. 2020;26:e177–e182. (PMID: 10.1016/j.bbmt.2020.04.013) Hashmi S, Carpenter P, Khera N, Tichelli A, Savani BN. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transpl. 2015;21:225–32. (PMID: 10.1016/j.bbmt.2014.06.035) Majhail NS, Rizzo JD. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transpl. 2013;48:1145–51. (PMID: 10.1038/bmt.2012.258) Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transpl. 2013;19:1498–501. (PMID: 10.1016/j.bbmt.2013.07.020) Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–9. (PMID: 21464398310774210.1200/JCO.2010.33.7212) Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341:14–21. (PMID: 1038793710.1056/NEJM199907013410103) Chow EJ, Cushing-Haugen KL, Cheng GS, Boeckh M, Khera N, Lee SJ, et al. Morbidity and mortality differences between hematopoietic cell transplantation survivors and other cancer survivors. J Clin Oncol. 2017;35:306–+. (PMID: 2787056810.1200/JCO.2016.68.8457) Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121:758–65. Hashmi SK, Bredeson C, Duarte RF, Farnia S, Ferrey S, Fitzhugh C, et al. National institutes of health blood and marrow transplant late effects initiative: the healthcare delivery working group report. Biol Blood Marrow Transpl. 2017;23:717–25. (PMID: 10.1016/j.bbmt.2016.09.025) Bevans M, El-Jawahri A, Tierney DK, Wiener L, Wood WA, Hoodin F, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the patient-centered outcomes working group report. Biol Blood Marrow Transpl. 2017;23:538–51. (PMID: 10.1016/j.bbmt.2016.09.011) Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani BN, Shelburne N. National institutes of health hematopoietic cell transplantation late effects initiative: developing recommendations to improve survivorship and long-term outcomes. Biol Blood Marrow Transpl. 2017;23:6–9. (PMID: 10.1016/j.bbmt.2016.10.020) Shaw BE, Hahn T, Martin PJ, Mitchell SA, Petersdorf EW, Armstrong GT, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the research methodology and study design working group report. Biol Blood Marrow Transpl. 2017;23:10–23. (PMID: 10.1016/j.bbmt.2016.08.018) Morton LM, Saber W, Baker KS, Barrett AJ, Bhatia S, Engels EA, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the subsequent neoplasms working group report. Biol Blood Marrow Transpl. 2017;23:367–78. (PMID: 10.1016/j.bbmt.2016.09.005) Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the immune dysregulation and pathobiology working group report. Biol Blood Marrow Transpl. 2017;23:870–81. (PMID: 10.1016/j.bbmt.2016.10.001) Armenian SH, Chemaitilly W, Chen M, Chow EJ, Duncan CN, Jones LW, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transpl. 2017;23:201–10. (PMID: 10.1016/j.bbmt.2016.08.019) Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transpl. 2006; 37: 249-61. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2006;12:138–51. (PMID: 10.1016/j.bbmt.2005.09.012) Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2012;5:1–30. (PMID: 22446607339308610.5144/1658-3876.2012.1) Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transpl. 2012;47:337–41. (PMID: 10.1038/bmt.2012.5) Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2012;18:348–71. (PMID: 10.1016/j.bbmt.2011.12.519) Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter. 2012;34:109–33. (PMID: 23049402345938310.5581/1516-8484.20120032) Desai AP, Go RS, Poonacha TK. Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress? Int J Cancer. 2021;148:429–36. (PMID: 3267422510.1002/ijc.33215) Neunert CE, Despotovic JM. Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. Pediatr Blood Cancer. 2019;66:e27569. (PMID: 3053743910.1002/pbc.27569) Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol. 2021;8:e229–e239. (PMID: 3363614310.1016/S2352-3026(20)30404-X) Gabelli M, Ademokun C, Cooper N, Amrolia PI. Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting. Br J Haematol. 2022;196:45–62. Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018;24:4633–42. (PMID: 2970381910.1158/1078-0432.CCR-17-3044) Nawas MT, Schetelig J, Damm F, Levine RL, Perales MA, Giralt SA, et al. The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Rev. 2021;46:100744. (PMID: 3289643510.1016/j.blre.2020.100744) Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21. (PMID: 28636844671750910.1056/NEJMoa1701719) Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375–85. (PMID: 3040357310.1200/JCO.2018.79.2184) Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598–605. (PMID: 28068180545570710.1200/JCO.2016.71.6712) Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant. 2008;41:997–1003. (PMID: 1843842510.1038/bmt.2008.99) Chaturvedi S, Neff A, Nagler A, Savani U, Mohty M, Savani BN. Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 2016;51:473–8. (PMID: 10.1038/bmt.2015.308) Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, et al. Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol. 2016;95:1457–64. (PMID: 2710300810.1007/s00277-016-2673-3) Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Battles K, et al. Venous thromboembolism in autologous blood or marrow transplantation survivors: a report from the blood or marrow transplant survivor study. Biol Blood Marrow Transpl. 2019;25:2261–6. (PMID: 10.1016/j.bbmt.2019.06.032) Rangarajan HG, Stanek JR, Abu-Arja R, Bajwa RPS, Auletta JJ, Lee DA, et al. Venous thromboembolism in pediatric hematopoietic cell transplant: a multicenter cohort study. Biol Blood Marrow Transpl. 2018;24:337–42. (PMID: 10.1016/j.bbmt.2017.10.038) Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, et al. Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. Br J Haematol. 2019;186:367–70. (PMID: 30883690776890610.1111/bjh.15866) Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, et al. Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Adv. 2021;5:4102–11. (PMID: 34461633894564110.1182/bloodadvances.2021004341) Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, et al. Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017;102:1185–91. (PMID: 28341735556602310.3324/haematol.2017.164012) Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, et al. Characteristics of late fatal infections after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:362–8. (PMID: 10.1016/j.bbmt.2018.09.031) Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35:2885–94. (PMID: 34079042817136210.1038/s41375-021-01302-5) Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011;96:1231–5. (PMID: 21546495314891910.3324/haematol.2011.041913) Perkins JL, Chen Y, Harris A, Diller L, Stovall M, Armstrong GT, et al. Infections among long-term survivors of childhood and adolescent. Cancer A Rep. Child Cancer Survivor Study Cancer. 2014;120:2514–21. Foord AM, Cushing-Haugen KL, Boeckh MJ, Carpenter PA, Flowers MED, Lee SJ, et al. Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. Blood Adv. 2020;4:1232–41. (PMID: 32227211716027410.1182/bloodadvances.2020001470) Dadwal SS, Hohl TM, Fisher CE, Boeckh M, Papanicolaou G, Carpenter PA, et al. American society of transplantation and cellular therapy series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients. Transpl Cell Ther. 2021;27:201–11. (PMID: 10.1016/j.jtct.2020.10.003) Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25:: 382–8. (PMID: 1676748610.1007/s10096-006-0149-4) Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2003;32:515–22. (PMID: 10.1038/sj.bmt.1704162) Caselli D, Petris MG, Rondelli R, Carraro F, Colombini A, Muggeo P, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr. 2014;164:389–92.e381. (PMID: 2425279310.1016/j.jpeds.2013.10.021) Carpenter PA, Papanicolaou G, Chemaly RF, Boeckh M, Savani BN. American society for transplantation and cellular therapy infectious disease guidelines: preface to the series. Transpl Cell Ther. 2021;27:103–4. (PMID: 10.1016/j.jtct.2020.10.004) Yong MK, Shigle TL, Kim Y-J, Carpenter PA, Chemaly RF, Papanicolaou GA. American Society for Transplantation and Cellular Therapy Series:# 4-Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27:957–67. (PMID: 3456031010.1016/j.jtct.2021.09.010) Satlin MJ, Weissman SJ, Carpenter PA, Seo SK, Shelburne SA. American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales infection prevention and management after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27:108–14. (PMID: 3378154510.1016/j.jtct.2020.10.001) Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, et al. American society for transplantation and cellular therapy series: #3—prevention of cytomegalovirus infection and disease after hematopoietic. Cell Transpl Transpl Cell Ther. 2021;27:707–19. Alonso CD, Maron G, Kamboj M, Carpenter PA, Gurunathan A, Mullane KM, et al. American Society for Transplantation and Cellular Therapy Series: #5—Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients. Transplant Cell Ther. 2022;28:225–32. (PMID: 3520289110.1016/j.jtct.2022.02.013) Neofytos D, Steinbach WJ, Hanson K, Carpenter PA, Papanicolaou GA, Slavin MA. American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients. Transplant Cell Ther. 2023;29:222–7. (PMID: 3664974810.1016/j.jtct.2023.01.011) Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transpl. 2015;21:1167–87. (PMID: 10.1016/j.bbmt.2015.03.024) Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transpl. 2009;15:1143–238. (PMID: 10.1016/j.bbmt.2009.06.019) Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Newburger JW et al. Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A. 2007. Taggart C, Neumann N, Alonso PB, Lane A, Pate A, Stegman A, et al. Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1382–6. (PMID: 10.1016/j.bbmt.2019.03.017) Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H et al. Return to work among young adult survivors of allogeneic hematopoietic cell transplantation in the United States. Transpl Cel Ther. 2021; 27. ARTN 679.e110.1016/j.jtct.2021.04.013. Bhatt NS, Meyer C, Mau LW, Broglie L, Devine S, Choi SW, et al. Return-to-school practices for pediatric hematopoietic cell transplantation recipients during the COVID-19 Pandemic. Transpl Cell Ther. 2022;28:54.e51–54.e54. Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200–e212. (PMID: 3074496310.1016/S1473-3099(18)30600-5) FACT‐JACIE. International standards for hematopoietic cellular therapy product collection, processing, and administration. In: Foundation for the Accreditation of Cellular Therapy (FACT) and Joint …, 2018. Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GMT, Huang JT, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a children’s oncology group report. Biol Blood Marrow Transpl. 2016;22:782–95. (PMID: 10.1016/j.bbmt.2016.01.023) Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016;127:2824–32. (PMID: 2704821210.1182/blood-2015-12-550475) Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–e100. (PMID: 2431147910.1093/cid/cit684) (CDC) CfDCaP. Advisory Committee on Immunization Practices (ACIP) General Best Guidance for Immunization: Altered Immunocompetence. In. Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2022;196:884–91. (PMID: 3471344110.1111/bjh.17918) Dioverti V, Boghdadly ZE, Shahid Z, Waghmare A, Abidi MZ, Pergam S et al. Revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022). Transpl Cell Ther 2022;28:810–821. Murray SM, Barbanti M, Campbell C, Brown A, Chen L, Dhanapal J, et al. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant. Br J Haematol. 2022;198:668-79. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27:770–81. (PMID: 1911470210.1200/JCO.2008.16.8450) Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T–and a side order of IgG, to go?–Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596. (PMID: 31416717681087110.1016/j.blre.2019.100596) Doan A, Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Cancer 2018;65. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259–75. (PMID: 3492310710.1016/j.annonc.2021.12.003) Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136:925–35. (PMID: 32582924744116810.1182/blood.2019004000) Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021;18:363–78. (PMID: 33495553833574610.1038/s41571-020-00456-y) Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30. (PMID: 2067519710.1016/j.clim.2010.06.012) Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective PREFACE. Bone Marrow Transpl. 2009;44:453–+. (PMID: 10.1038/bmt.2009.254) Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389–401.e381. (PMID: 10.1016/j.bbmt.2014.12.001) Nair S, Vanathi M, Mukhija R, Tandon R, Jain S, Ogawa Y. Update on ocular graft-versus-host disease. Indian J Ophthalmol. 2021;69:1038–50. (PMID: 33913829818664410.4103/ijo.IJO_2016_20) Tabbara KF, Al-Ghamdi A, Al-Mohareb F, Ayas M, Chaudhri N, Al-Sharif F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmol. 2009;116:1624–9. (PMID: 10.1016/j.ophtha.2009.04.054) Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol. 2013;27:215–22. (PMID: 24227989377022510.1016/j.sjopt.2013.06.007) Inamoto Y, Valdes-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transpl. 2019;54:662–73. (PMID: 10.1038/s41409-018-0340-0) Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transpl. 2019;54:648–61. (PMID: 10.1038/s41409-018-0339-6) Gurney JG, Ness KK, Rosenthal J, Forman SJ, Bhatia S, Baker KS. Visual auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer. 2006;106:1402–8. (PMID: 1645333510.1002/cncr.21752) Pavletic SZ, Lee SJ, Socie G, Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transpl. 2006;38:645–51. (PMID: 10.1038/sj.bmt.1705490) Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig. 2011;15:127–39. (PMID: 2085964510.1007/s00784-010-0450-6) Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904. (PMID: 907046910.1056/NEJM199703273361301) Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316–22. (PMID: 20926773303775310.1182/blood-2010-07-294629) Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1175–83. (PMID: 18971419263508310.1182/blood-2008-05-158782) Chen MH, Chang PM, Li WY, Hsiao LT, Hong YC, Liu CY, et al. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan. Bone Marrow Transpl. 2011;46:567–72. (PMID: 10.1038/bmt.2010.163) Yokota A, Ozawa S, Masanori T, Akiyama H, Ohshima K, Kanda Y, et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transpl. 2012;47:95–100. (PMID: 10.1038/bmt.2011.23) Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105:3802–11. (PMID: 15687239189509210.1182/blood-2004-09-3411) Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol. 2014;25:435–41. (PMID: 2439908110.1093/annonc/mdt558) Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23:223–36. (PMID: 2518914910.1007/s00520-014-2378-x) Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2012;18:1573–9. (PMID: 10.1016/j.bbmt.2012.04.009) Holtta P, Alaluusua S, Saarinen-Pihkala UM, Peltola J, Hovi L. Agenesis and microdontia of permanent teeth as late adverse effects after stem cell transplantation in young children. Cancer-Am Cancer Soc. 2005;103:181–90. Solh M, Arat M, Cao Q, Majhail NS, Weisdorf D. Late-onset noninfectious pulmonary complications in adult allogeneic hematopoietic cell transplant recipients. Transplantation. 2011;91:798–803. (PMID: 2140358610.1097/TP.0b013e31820c85fa) Wenger DS, Triplette M, Crothers K, Cheng GS, Hill JA, Milano F, et al. Incidence, risk factors, and outcomes of idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26:413–20. (PMID: 10.1016/j.bbmt.2019.09.034) Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183:1262–79. (PMID: 21531955326614010.1164/rccm.2007-413ST) Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129:448–55. (PMID: 27856461527038710.1182/blood-2016-08-693507) Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208–14. (PMID: 1264912610.1164/rccm.200212-1468OC) Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302:306–14. (PMID: 19602690735720910.1001/jama.2009.1018) Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2014;20:781–6. (PMID: 10.1016/j.bbmt.2014.02.011) Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight–new perspectives? Bone Marrow Transpl. 2013;48:1224–9. (PMID: 10.1038/bmt.2013.17) Fitch T, Myers KC, Dewan M, Towe C, Dandoy C. Pulmonary complications after pediatric stem cell transplant. Front Oncol. 2021;11:755878. (PMID: 34722309855045210.3389/fonc.2021.755878) Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood. 2003;102:3822–8. (PMID: 1286951610.1182/blood-2002-06-1813) Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakihana K, et al. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Bone Marrow Transpl. 2013;48:1317–23. (PMID: 10.1038/bmt.2013.116) Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;28:425–34. (PMID: 10.1038/sj.bmt.1703142) Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–92. (PMID: 17671231207732410.1182/blood-2007-03-082933) Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614–25. (PMID: 28232372539510210.3324/haematol.2016.150250) Rotz SJ, Ryan TD, Hayek SS. Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. J Thromb Thrombolysis. 2021;51:854–69. (PMID: 3323070410.1007/s11239-020-02344-9) Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers ME, Martin PJ, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med. 2011;155:21–32. (PMID: 2172729010.7326/0003-4819-155-1-201107050-00004) Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, et al. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv. 2018;2:1756–64. (PMID: 30037802605823910.1182/bloodadvances.2018019117) Rotz SJ, Ryan TD, Hlavaty J, George SA, El-Bietar J, Dandoy CE. Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant. Pediatr Blood Cancer. 2017; 64. Armenian SH, Sun CL, Shannon T, Mills G, Francisco L, Venkataraman K, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118:6023–9. (PMID: 21976673323466310.1182/blood-2011-06-358226) Tichelli A, Passweg J, Wojcik D, Rovo A, Harousseau JL, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203–10. (PMID: 1855640110.3324/haematol.12949) Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J-Cardiovascular Imaging. 2022;23:e333–e465. (PMID: 10.1093/ehjci/jeac106) Aziz-Bose R, Margossian R, Ames BL, Moss K, Ehrhardt MJ, Armenian SH, et al. Delphi panel consensus recommendations for screening and managing childhood cancer survivors at risk for cardiomyopathy. JACC CardioOncol. 2022;4:354–67. (PMID: 36213355953707210.1016/j.jaccao.2022.05.010) Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2009;43:49–54. (PMID: 10.1038/bmt.2008.263) Baker KS, Chow EJ, Goodman PJ, Leisenring WM, Dietz AC, Perkins JL, et al. Impact of treatment exposures on cardiovascular risk and insulin resistance in childhood cancer survivors. Cancer Epidemiol Biomark Prev. 2013;22:1954–63. (PMID: 10.1158/1055-9965.EPI-13-0610) Greenfield DM, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, et al. Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. Bone Marrow Transpl. 2021;56:2820–5. (PMID: 10.1038/s41409-021-01414-7) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5. (PMID: 1980565410.1161/CIRCULATIONAHA.109.192644) Kockx M, Jessup W, Kritharides L, Cyclosporin A. and atherosclerosis–cellular pathways in atherogenesis. Pharm Ther. 2010;128:106–18. (PMID: 10.1016/j.pharmthera.2010.06.001) Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol. 2014;165:364–74. (PMID: 24467690427173410.1111/bjh.12754) DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, et al. Metabolic syndrome and cardiovascular disease after hematopoietic cell transplantation: screening and preventive practice recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transpl. 2016;22:1493–503. (PMID: 10.1016/j.bbmt.2016.05.007) Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transpl. 2012;47:619–25. (PMID: 10.1038/bmt.2011.118) Blaser BW, Kim HT, Alyea EP 3rd, Ho VT, Cutler C, Armand P, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2012;18:575–83. (PMID: 10.1016/j.bbmt.2011.08.003) Pophali PA, Klotz JK, Ito S, Jain NA, Koklanaris E, Le RQ, et al. Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol. 2014;42:83–9. (PMID: 2414109210.1016/j.exphem.2013.07.003) Kyle UG, Chalandon Y, Miralbell R, Karsegard VL, Hans D, Trombetti A, et al. Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. Bone Marrow Transpl. 2005;35:1171–7. (PMID: 10.1038/sj.bmt.1704996) Friedman DN, Moskowitz CS, Hilden P, Howell RM, Weathers RE, Smith SA, et al. Radiation dose and volume to the pancreas and subsequent risk of diabetes mellitus: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2020;112:525–32. (PMID: 3132922510.1093/jnci/djz152) Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012;120:4505–12. (PMID: 23034279351223010.1182/blood-2012-06-437178) Oudin C, Auquier P, Bertrand Y, Contet A, Kanold J, Sirvent N, et al. Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study. Bone Marrow Transpl. 2015;50:1438–44. (PMID: 10.1038/bmt.2015.167) Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463–71. (PMID: 1766435410.1182/blood-2006-10-054080) Leger KJ, Baker KS, Cushing-Haugen KL, Flowers MED, Leisenring WM, Martin PJ, et al. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer. 2018;124:1507–15. (PMID: 2931550710.1002/cncr.31227) Leger KJ, Cushing-Haugen K, Hansen JA, Fan W, Leisenring WM, Martin PJ, et al. Clinical and genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors. Biol Blood Marrow Transpl. 2016;22:1094–101. (PMID: 10.1016/j.bbmt.2016.02.017) Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38:3–12. (PMID: 3023139610.1200/EDBK_100015) Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood J Am Soc Hematol. 2015;125:606–15. Jorgensen AY, Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Rosenschold PM, et al. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin’s lymphoma. Acta Oncol. 2013;52:1559–65. (PMID: 2404734010.3109/0284186X.2013.813636) Nomura K, Iizuka T, Kaji D, Asano-Mori Y, Ochiai Y, Suzuki Y, et al. Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021;147:2137–44. (PMID: 3338704210.1007/s00432-020-03500-7) Gutierrez CA, Raval MV, Vester HR, Chaudhury S, von Allmen D, Rothstein DH. Surgical treatment of intestinal complications of graft versus host disease in the pediatric population: Case series and review of literature. J Pediatr Surg. 2017;52:1718–22. (PMID: 2871116810.1016/j.jpedsurg.2017.06.022) Gini A, Meester RGS, Keshavarz H, Oeffinger KC, Ahmed S, Hodgson DC, et al. Cost-effectiveness of colonoscopy-based colorectal cancer screening in childhood cancer survivors. J Natl Cancer Inst. 2019;111:1161–9. (PMID: 30980665685598610.1093/jnci/djz060) Teepen JC, Kok JL, van Leeuwen FE, Tissing WJE, Dolsma WV, van der Pal HJ, et al. Colorectal adenomas and cancers after childhood cancer treatment: a DCOG-LATER record linkage study. J Natl Cancer Inst. 2018;110:758–67. (PMID: 2998609710.1093/jnci/djx266) Nottage K, McFarlane J, Krasin MJ, Li C, Srivastava D, Robison LL, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol. 2012;30:2552–8. (PMID: 2266554610.1200/JCO.2011.37.8760) Haghiri S, Fayech C, Mansouri I, Dufour C, Pasqualini C, Bolle S, et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transpl. 2021;56:1984–97. (PMID: 10.1038/s41409-021-01258-1) Sudour H, Mainard L, Baumann C, Clement L, Salmon A, Bordigoni P. Focal nodular hyperplasia of the liver following hematopoietic SCT. Bone Marrow Transpl. 2009;43:127–32. (PMID: 10.1038/bmt.2008.304) Pillon M, Carucci NS, Mainardi C, Carraro E, Zuliani M, Chemello L, et al. Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transpl. 2015;50:414–9. (PMID: 10.1038/bmt.2014.276) Anderson L, Gregg D, Margolis D, Casper J, Talano J. Focal nodular hyperplasia in pediatric allogeneic hematopoietic cell transplant: case series. Bone Marrow Transpl. 2010;45:1357–9. (PMID: 10.1038/bmt.2009.336) Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147–53. (PMID: 1914498610.1182/blood-2008-10-163493) Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16:606–17. (PMID: 2759965310.1016/S1473-3099(16)00118-3) Torres HA, Chong PP, De Lima M, Friedman MS, Giralt S, Hammond SP, et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transpl. 2015;21:1870–82. (PMID: 10.1016/j.bbmt.2015.07.033) McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51:1450–60. (PMID: 2037337010.1002/hep.23533) Sastry J, Young S, Shaw PJ. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. Bone Marrow Transpl. 2004;33:867–8. (PMID: 10.1038/sj.bmt.1704429) Akpek G, Valladares JL, Lee L, Margolis J, Vogelsang GB. Pancreatic insufficiency in patients with chronic graft-versus-host disease. Bone Marrow Transpl. 2001;27:163–6. (PMID: 10.1038/sj.bmt.1702769) Hingorani S. Renal complications of hematopoietic-cell transplantation. N. Engl J Med. 2016;374:2256–67. (PMID: 2727656310.1056/NEJMra1404711) Hingorani S, Pao E, Stevenson P, Schoch G, Laskin BL, Gooley T, et al. Changes in glomerular filtration rate and impact on long-term survival among adults after hematopoietic cell transplantation: a prospective cohort study. Clin J Am Soc Nephrol. 2018;13:866–73. (PMID: 29669818598968810.2215/CJN.10630917) Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transpl. 2021;56:1805–17. (PMID: 10.1038/s41409-021-01283-0) Schoettler M, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023;29:151–163. Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, et al. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2021;5:1–11. (PMID: 3357061910.1182/bloodadvances.2020003455) Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, et al. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020;95:1170–9. (PMID: 3261800010.1002/ajh.25922) Sklar C. Growth and endocrine disturbances after bone marrow transplantation in childhood. Acta Paediatr Suppl. 1995;411:57–61. (PMID: 856307110.1111/j.1651-2227.1995.tb13865.x) Brauner R, Adan L, Souberbielle JC, Esperou H, Michon J, Devergie A et al. Contribution of growth hormone deficiency to the growth failure that follows bone marrow transplantation. J Pediatr. 1997;130:785–92. Ogilvy-Stuart AL, Clark DJ, Wallace WH, Gibson BE, Stevens RF, Shalet SM, et al. Endocrine deficit after fractionated total body irradiation. Arch Dis Child. 1992;67:1107–10. (PMID: 1417055179360910.1136/adc.67.9.1107) Alter CA, Thornton PS, Willi SM, Bunin N, Moshang T Jr. Growth in children after bone marrow transplantation for acute myelogenous leukemia as compared to acute lymphocytic leukemia. J Pediatr Endocrinol Metab. 1996;9:51–7. (PMID: 888713310.1515/JPEM.1996.9.1.51) Shalet SM, Toogood A, Rahim A, Brennan BM. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev. 1998;19:203–23. (PMID: 957003710.1210/edrv.19.2.0329) Sanders JE, Buckner CD, Sullivan KM, Doney K, Appelbaum F, Witherspoon R, et al. Growth and development in children after bone marrow transplantation. Horm Res. 1988;30:92–7. (PMID: 307403210.1159/000181036) Sanders JE, Pritchard S, Mahoney P, Amos D, Buckner CD, Witherspoon RP, et al. Growth and development following marrow transplantation for leukemia. Blood. 1986;68:1129–35. (PMID: 353318010.1182/blood.V68.5.1129.1129) Shalet SM, Crowne EC, Didi MA, Ogilvy-Stuart AL, Wallace WH. Irradiation-induced growth failure. Baillieres Clin Endocrinol Metab. 1992;6:513–26. (PMID: 152454910.1016/S0950-351X(05)80109-0) Couto-Silva AC, Trivin C, Esperou H, Michon J, Baruchel A, Lemaire P, et al. Final height and gonad function after total body irradiation during childhood. Bone Marrow Transpl. 2006;38:427–32. (PMID: 10.1038/sj.bmt.1705455) Chemaitilly W, Boulad F, Heller G, Kernan NA, Small TN, O’Reilly RJ et al. Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. Bone Marrow Transpl 2007; 40: 29–35. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood. 2005;105:1348–54. (PMID: 1545448110.1182/blood-2004-07-2528) Wilcox NS, Rotz SJ, Mullen M, Song EJ, Ky Hamilton B, Moslehi J, et al. Sex-specific cardiovascular risks of cancer and its therapies. Circ Res. 2022;130:632–51. (PMID: 35175846891544410.1161/CIRCRESAHA.121.319901) Baker KS, Ness KK, Weisdorf D, Francisco L, Sun CL, Forman S, et al. Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia. 2010;24:2039–47. (PMID: 20861916300555510.1038/leu.2010.210) Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood. 2009;113:306–8. (PMID: 18838614261564710.1182/blood-2008-08-173005) Farhadfar N, Stan MN, Shah P, Sonawane V, Hefazi MT, Murthy HS, et al. Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes. Bone Marrow Transpl. 2018;53:977–82. (PMID: 10.1038/s41409-018-0109-5) Medinger M, Zeiter D, Heim D, Halter J, Gerull S, Tichelli A, et al. Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Leuk Res. 2017;58:43–7. (PMID: 2843388210.1016/j.leukres.2017.04.003) Savani BN, Koklanaris EK, Le Q, Shenoy A, Goodman S, Barrett AJ. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transpl. 2009;15:377–81. (PMID: 10.1016/j.bbmt.2008.11.032) Cattoni A, Molinari S, Gaiero A, De Lorenzo P, Fichera G, Riva B. et al. Thyroid disorders following hematopoietic stem cell transplantation in childhood: impact of conditioning regimen on thyroid dysfunction, volume changes, and occurrence of nodules. Transpl Cell Ther. 2022;28:506.e501–506.e512. (PMID: 10.1016/j.jtct.2022.05.040) Tatevossian R, Blair JC, Plowman PN, Savage MO, Shankar AG. Thyrotoxicosis after matched unrelated bone marrow transplantation. J Pediatr Hematol Oncol. 2004;26:529–31. (PMID: 1528459410.1097/01.mph.0000132937.73264.55) Khera N, Storer B, Flowers ME, Carpenter PA, Inamoto Y, Sandmaier BM, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30:71–7. (PMID: 2214773710.1200/JCO.2011.38.4594) Thygesen KH, Schjodt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transpl. 2012;47:716–24. (PMID: 10.1038/bmt.2011.169) Haavisto A, Mathiesen S, Suominen A, Lahteenmaki P, Sorensen K, Ifversen M, et al. Male sexual function after allogeneic hematopoietic stem cell transplantation in childhood: a multicenter study. Cancers. 2020;12:1786. Syrjala KL, Schoemans H, Yi JC, Langer SL, Mukherjee A, Onstad L, et al. Sexual functioning in long-term survivors of hematopoietic cell transplantation. Transpl Cell Ther. 2021;27:80.e81–80.e12. (PMID: 10.1016/j.bbmt.2020.09.027) Nørskov KH, Schmidt M, Jarden M. Patients’ experience of sexuality 1-year after allogeneic haematopoietic stem cell transplantation. Eur J Oncol Nurs. 2015;19:419–26. (PMID: 2563184610.1016/j.ejon.2014.12.005) Wong FL, Francisco L, Togawa K, Kim H, Bosworth A, Atencio L, et al. Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation. Blood. 2013;122:3973–81. (PMID: 24159171385411510.1182/blood-2013-05-499806) Tsatsou I, Mystakidou K, Panagou E, Adamakidou T, Kalemikerakis I, Vastardi M, et al. Sexuality and quality of life of patients with hematologic malignancy and hematopoietic stem cell transplantation: a critical review. J BUON. 2020;25:1693–706. (PMID: 33099903) Gerstl B, Sullivan E, Koch J, Wand H, Ives A, Mitchell R, et al. Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2019;27:4451–60. (PMID: 3154130610.1007/s00520-019-05020-8) Salooja N, Shoham Z, Dalle JH. Endocrine Disorders, Fertility and Sexual Health. In: Carreras E, Dufour C, Mohty M, Kröger N (eds). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer Copyright 2019, EBMT and the Author(s). Cham (CH), 2019, pp 421-7. Bourlon C, Riviello-Goya S, Acosta-Medina AA, Caballero-Landinez RE, Manrique-Rubio A, Teran-De-la-Sancha K, et al. Outcomes and challenges of reproductive health in hematopoietic stem cell transplantation survivors. Biol Blood Marrow Transpl. 2020;26:2127–31. (PMID: 10.1016/j.bbmt.2020.07.007) Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62:738–44. (PMID: 1593655410.1016/j.ijrobp.2004.11.038) Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, et al. male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the late effects and quality of life working committee of the center for international blood and marrow transplant research and transplant complications working party of the European Society of Blood and Marrow Transplantation. Transpl Cell Ther. 2022;28:335.e331–335.e317. (PMID: 10.1016/j.jtct.2021.10.013) Nahata L, Woodruff TK, Quinn GP, Meacham LR, Chen D, Appiah LC, et al. Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations? J Assist Reprod Genet. 2020;37:1323–6. (PMID: 32390071731163010.1007/s10815-020-01794-7) Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019;3:Cd008018. (PMID: 30827035) Hur C, Rehmer J, Flyckt R, Falcone T. Uterine factor infertility: a clinical review. Clin Obstet Gynecol. 2019;62:257–70. (PMID: 3102192810.1097/GRF.0000000000000448) Fenig E, Mishaeli M, Kalish Y, Lishner M. Pregnancy and radiation. Cancer Treat Rev. 2001;27:1–7. (PMID: 1123777310.1053/ctrv.2000.0193) Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005; 21–5. Green DM, Sklar CA, Boice JD Jr., Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2374–81. (PMID: 19364956267792310.1200/JCO.2008.21.1839) Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transpl. 2002;30:543–6. (PMID: 10.1038/sj.bmt.1703711) Parker P, Chao NJ, Ben-Ezra J, Slatkin N, Openshaw H, Niland JC, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Med (Baltim). 1996;75:279–85. (PMID: 10.1097/00005792-199609000-00004) Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatol (Oxf). 2003;42:34–9. (PMID: 10.1093/rheumatology/keg025) Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O, et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med. 1994;120:993–8. (PMID: 818514810.7326/0003-4819-120-12-199406150-00004) Markusse HM, Dijkmans BA, Fibbe WE. Eosinophilic fasciitis after allogeneic bone marrow transplantation. J Rheumatol. 1990;17:692–4. (PMID: 2359082) Oda K, Nakaseko C, Ozawa S, Nishimura M, Saito Y, Yoshiba F, et al. Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. Bone Marrow Transpl. 2009;43:159–67. (PMID: 10.1038/bmt.2008.297) Tse S, Saunders EF, Silverman E, Vajsar J, Becker L, Meaney B. Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. Bone Marrow Transpl. 1999;23:397–9. (PMID: 10.1038/sj.bmt.1701575) Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Jt Bone Spine. 2011;78:41–4. (PMID: 10.1016/j.jbspin.2010.02.025) Inamoto Y, Lee SJ, Onstad LE, Flowers MED, Hamilton BK, Jagasia MH, et al. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Adv. 2020;4:40–6. (PMID: 31899796696047110.1182/bloodadvances.2019000918) Inamoto Y, Pidala J, Chai X, Kurland BF, Weisdorf D, Flowers ME, et al. Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol. 2014;66:1044–52. (PMID: 24757155401435610.1002/art.38293) Buxbaum NP, Pavletic SZ. Autoimmunity following allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:2017. (PMID: 32983144747982410.3389/fimmu.2020.02017) Bar M, Ott SM, Lewiecki EM, Sarafoglou K, Wu JY, Thompson MJ, et al. Bone health management after hematopoietic cell transplantation: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2020;26:1784–802. (PMID: 10.1016/j.bbmt.2020.07.001) Savani BN, Donohue T, Kozanas E, Shenoy A, Singh AK, Childs RW, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:517–20. (PMID: 10.1016/j.bbmt.2007.01.085) Tauchmanova L, Colao A, Lombardi G, Rotoli B, Selleri C. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007;92:4536–45. (PMID: 1791117510.1210/jc.2006-2870) Pirsl F, Curtis LM, Steinberg SM, Tella SH, Katic M, Dobbin M, et al. Characterization and risk factor analysis of osteoporosis in a large cohort of patients with chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2016;22:1517–24. (PMID: 10.1016/j.bbmt.2016.04.012) Schimmer AD, Mah K, Bordeleau L, Cheung A, Ali V, Falconer M, et al. Decreased bone mineral density is common after autologous blood or marrow transplantation. Bone Marrow Transpl. 2001;28:387–91. (PMID: 10.1038/sj.bmt.1703149) Yao S, McCarthy PL, Dunford LM, Roy DM, Brown K, Paplham P, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transpl. 2008;41:393–8. (PMID: 10.1038/sj.bmt.1705918) Petropoulou AD, Porcher R, Herr AL, Devergie A, Brentano TF, Ribaud P, et al. Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;89:1354–61. (PMID: 2021648010.1097/TP.0b013e3181d84c8e) Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transpl. 2001;7:257–64. (PMID: 10.1053/bbmt.2001.v7.pm11400947) Bechard LJ, Gordon C, Feldman HA, Venick R, Gura K, Guinan EC, et al. Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2015;62:687–92. (PMID: 25630874474302510.1002/pbc.25370) Swauger S, Sabulski A, Hornung L, Wasserman H, Myers KC, Howell JC. Bone health outcomes at 1 year after hematopoietic stem cell transplantation in a heterogeneous pediatric population. Transpl Cell Ther. 2022;28:44.e41–44.e46. (PMID: 10.1016/j.jtct.2021.08.019) Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103:3635–43. (PMID: 1463080510.1182/blood-2003-09-3081) Yao S, Smiley SL, West K, Lamonica D, Battiwalla M, McCarthy PL Jr, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2010;16:1130–7. (PMID: 10.1016/j.bbmt.2010.02.017) Petryk A, Polgreen LE, Zhang L, Hodges JS, Dengel DR, Hoffmeister PA, et al. Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant. Bone Marrow Transpl. 2014;49:258–63. (PMID: 10.1038/bmt.2013.156) McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transpl. 2011;46:1–9. (PMID: 10.1038/bmt.2010.198) McClune B, Majhail NS, Flowers ME. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol. 2012;49:59–65. (PMID: 2222178510.1053/j.seminhematol.2011.10.007) Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476–81. (PMID: 194442610.1056/NEJM199111213252104) Li X, Brazauskas R, Wang Z, Al-Seraihy A, Baker KS, Cahn JY, et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transpl. 2014;20:587–92. (PMID: 10.1016/j.bbmt.2013.12.567) Law AD, Bhella S, Pasic I, Lam W, Michelis FV, Gerbitz A, et al. Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2021;100:1311–9. (PMID: 3371036610.1007/s00277-021-04480-5) Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, et al. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020;4:983–92. (PMID: 32168378709402210.1182/bloodadvances.2019001126) Socie G, Cahn JY, Carmelo J, Vernant JP, Jouet JP, Ifrah N, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol. 1997;97:865–70. (PMID: 921719010.1046/j.1365-2141.1997.1262940.x) McAvoy S, Baker KS, Mulrooney D, Blaes A, Arora M, Burns LJ, et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2010;16:1231–6. (PMID: 10.1016/j.bbmt.2010.03.008) Carpenter PA. How I conduct a comprehensive chronic graft-versus-host disease assessment. Blood. 2011;118:2679–87. (PMID: 2171960010.1182/blood-2011-04-314815) Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transpl. 2006;12:375–96. (PMID: 10.1016/j.bbmt.2006.02.003) Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. Blood. 2019;133:1191–1200. (PMID: 30674472641848010.1182/blood-2018-04-785899) de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry. 2000;68:36–40. Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology. 2003;60:842–8. (PMID: 1262924410.1212/01.WNL.0000046522.38465.79) Lehky T, Fernandez IP, Krakow EF, Connelly-Smith L, Salit RB, Vo P, et al. Neuropathy and muscle cramps in autologous and allogeneic hematopoietic cell transplantation survivors. Transpl Cell Ther. 2022;28:608.e601–608.e609. (PMID: 10.1016/j.jtct.2022.06.009) Dowling MR, Li S, Dey BR, McAfee SL, Hock HR, Spitzer TR, et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transpl. 2018;53:199–206. (PMID: 10.1038/bmt.2017.239) Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation. 2002; 74:1303–9. Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica. 2013;98:437–43. (PMID: 22899581365993910.3324/haematol.2012.069559) Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2001;7:154–62. (PMID: 10.1053/bbmt.2001.v7.pm11302549) Coplin WM, Cochran MS, Levine SR, Crawford SW. Stroke after bone marrow transplantation: frequency, aetiology and outcome. Brain. 2001;124:1043–51. (PMID: 1133570610.1093/brain/124.5.1043) Gangaraju R, Chen Y, Hageman L, Wu J, Landier W, Francisco LF et al. Stroke Risk in Blood or Marrow Transplant (BMT) Survivors-a Report from the BMT Survivor Study (BMTSS). Blood. 2019;134:3298. Kenney LB, Ames BL, Huang MS, Yock T, Bowers DC, Nekhlyudov L et al. Consensus recommendations for managing childhood cancer survivors at risk for stroke after cranial irradiation: a Delphi study. Neurology. 2022. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children’s Oncology Group. Pediatrics. 2007;120:e1229–1236. (PMID: 1797471610.1542/peds.2007-0178) Holmqvist AS, Chen YJ, Wu J, Hageman L, Battles KD, Francisco LF, et al. Severe/life-threatening/fatal chronic health conditions (chcs) after allogeneic blood or marrow transplantation (BMT) in childhood - a Report from the BMT Survivor Study (BMTSS). Blood. 2020;136:12–3. (PMID: 10.1182/blood-2020-133895) Przybylyski A, Esper P. Early recognition and management of posterior reversible encephalopathy syndrome: a newly recognized complication in patients receiving tyrosine kinase inhibitors. Clin J Oncol Nurs. 2016;20:305–8. (PMID: 2720629710.1188/16.CJON.305-308) Tavil B, Isgandarova F, Bayhan T, Unal S, Kuskonmaz B, Gumruk F, et al. Sorafenib-induced posterior reversible encephalopathy syndrome in a child with FLT3-ITD-positive acute myeloid leukemia. J Pediatr Hematol Oncol. 2016;38:240–2. (PMID: 2690766210.1097/MPH.0000000000000521) Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory Non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;; 34:1104–11. (PMID: 2688458210.1200/JCO.2014.59.1586) Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40. (PMID: 19264918268613410.1182/blood-2008-10-186999) Isidoro L, Pires P, Rito L, Cordeiro G. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. 2014;2014:bcr2013201781. (PMID: 24403383390243610.1136/bcr-2013-201781) Takao M. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies]. Brain Nerve. 2013;65:: 1363–74. (PMID: 24200614) Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transpl. 2015;50:1030–6. (PMID: 10.1038/bmt.2015.76) Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kuhl JS, Mousset S, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica. 2011;96:142–9. (PMID: 2085186810.3324/haematol.2010.029876) Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005;23: 6596–606. Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011;29:2397–404. (PMID: 21537032310775410.1200/JCO.2010.33.9119) Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transpl. 2018;53:535–55. (PMID: 10.1038/s41409-017-0055-7) Schofield HT, Fabrizio VA, Braniecki S, Pelletier W, Eissa H, Murphy B, et al. Monitoring neurocognitive functioning after pediatric cellular therapy or hematopoietic cell transplant: guidelines From the COG neurocognition in cellular therapies task force. Transpl Cell Ther. 2022;28:625–36. (PMID: 10.1016/j.jtct.2022.06.027) Lefvert AK, Bjorkholm M. Antibodies against the acetylcholine receptor in hematologic disorders: implications for the development of myasthenia gravis after bone marrow grafting. N. Engl J Med. 1987;317:170. (PMID: 329908710.1056/NEJM198707163170314) Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis. 2011;2011:474512. (PMID: 218607843155972) Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol. 2006;6:550–6. (PMID: 1650491810.1016/j.intimp.2005.11.016) Stephenson AL, Mackenzie IRA, Levy RD, Road J. Myositis associated graft-versus-host-disease presenting as respiratory muscle weakness. Thorax. 2001;56:82–4. (PMID: 11120911174589610.1136/thorax.56.1.82) Choi W-C, Jung Y-H, Yang Y-I, Bae J-S. Polymyositis after bone marrow transplantation: as an uncommon manifestation of chronic graft-versus-host disease? or autoimmune. Process? Ann Clin Neurophysiol. 2011;13:58–60. Matsuo Y, Kamezaki K, Takeishi S, Takenaka K, Eto T, Nonami A, et al. Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Intern Med. 2009;48:1453–6. (PMID: 1968759710.2169/internalmedicine.48.2003) Sostak P, Padovan CS, Eigenbrod S, Roeber S, Segerer S, Schankin C, et al. Cerebral angiitis in four patients with chronic GVHD. Bone Marrow Transpl. 2010;45:1181–8. (PMID: 10.1038/bmt.2009.323) Grauer O, Wolff D, Bertz H, Greinix H, Kuhl JS, Lawitschka A, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain. 2010;133:2852–65. (PMID: 2084694410.1093/brain/awq245) Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood. 2011;118:4723–31. (PMID: 21821714320828610.1182/blood-2011-04-348730) Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867–73. (PMID: 16788100189559310.1182/blood-2006-02-003954) Esser P, Kuba K, Scherwath A, Johansen C, Schwinn A, Schirmer L, et al. Stability and priority of symptoms and symptom clusters among allogeneic HSCT patients within a 5-year longitudinal study. J Pain Symptom Manag. 2017;54:493–500. (PMID: 10.1016/j.jpainsymman.2017.07.012) Esser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, et al. Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT. Bone Marrow Transpl. 2017;52:753–8. (PMID: 10.1038/bmt.2016.344) Esser P, Kuba K, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, et al. Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study. J Cancer Survivorship. 2017;11:203–10. (PMID: 10.1007/s11764-016-0579-7) Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, et al. Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany. Bone Marrow Transpl. 2017;52:1651–7. (PMID: 10.1038/bmt.2017.190) Mosher CE, DuHamel KN, Rini C, Corner G, Lam J, Redd WH. Quality of life concerns and depression among hematopoietic stem cell transplant survivors. Support Care Cancer. 2011;19:1357–65. (PMID: 2066175310.1007/s00520-010-0958-y) Andrykowski MA, Bishop MM, Hahn EA, Cella DF, Beaumont JL, Brady MJ, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23:599–608. (PMID: 1565950710.1200/JCO.2005.03.189) Bhatt NS. Prevalence and determinants of return to work as a patient-centered outcome in survivors of hematopoietic cell transplantation. Curr Hematol Malignancy Rep. 2022;17:228–42. (PMID: 10.1007/s11899-022-00678-0) Syrjala KL, Langer SL, Abrams JR, Storer B, Sanders JE, Flowers ME, et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA. 2004;291:2335–43. (PMID: 1515020510.1001/jama.291.19.2335) Bush NE, Donaldson GW, Haberman MH, Dacanay R, Sullivan KM. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: A longitudinal follow-up of 415 patients. Biol Blood Marrow Transpl. 2000;6:576–91. (PMID: 10.1016/S1083-8791(00)70067-X) Tichelli A, Gerull S, Holbro A, Buser A, Nair G, Medinger M, et al. Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52:1436. (PMID: 10.1038/bmt.2017.115) Bieri S, Roosnek E, Helg C, Verholen F, Robert D, Chapuis B, et al. Quality of life and social integration after allogeneic hematopoietic SCT. Bone Marrow Transpl. 2008;42:819–27. (PMID: 10.1038/bmt.2008.253) Wong FL, Francisco L, Togawa K, Bosworth A, Gonzales M, Hanby C, et al. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns. Blood. 2010;115:2508–19. (PMID: 20089962284590310.1182/blood-2009-06-225631) Heinonen H, Volin L, Uutela A, Zevon M, Barrick C, Ruutu T. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation. Ann Hematol. 2001;80:137–43. (PMID: 1132089710.1007/s002770000249) Morrison EJ, Ehlers SL, Bronars CA, Patten CA, Brockman TA, Cerhan JR, et al. Employment status as an indicator of recovery and function one year after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22:1690–5. (PMID: 10.1016/j.bbmt.2016.05.013) Hahn T, Paplham P, Austin-Ketch T, Zhang Y, Grimmer J, Burns M, et al. Ascertainment of unmet needs and participation in health maintenance and screening of adult hematopoietic cell transplantation survivors followed in a formal survivorship program. Biol Blood Marrow Transpl. 2017;23:1968–73. (PMID: 10.1016/j.bbmt.2017.07.024) Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transpl. 2012;47:473–82. (PMID: 10.1038/bmt.2011.107) Lof CM, Winiarski J, Ljungman P, Forinder U. The socioeconomic and psychosocial circumstances of adult long-term survivors of hematopoietic stem cell transplantation in childhood. Pediatr Transpl. 2011;15:691–8. (PMID: 10.1111/j.1399-3046.2011.01537.x) Parisek M, Loss J, Holler E, Barata A, Weber D, Edinger M, et al. "This Graft-vs.-Host Disease Determines My Life. That’s It."-A qualitative analysis of the experiences and needs of allogenic hematopoietic stem cells transplantation survivors in Germany. Front Public Health. 2021;9:687675. (PMID: 34277549828076610.3389/fpubh.2021.687675) Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, et al. Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2014;49:1426–31. (PMID: 10.1038/bmt.2014.166) Gruber U, Fegg M, Buchmann M, Kolb HJ, Hiddemann W. The long-term psychosocial effects of haematopoetic stem cell transplantation. Eur J Cancer Care (Engl). 2003;12:249–56. (PMID: 12919304) Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, et al. Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. Bone Marrow Transpl. 2019;54:611–5. (PMID: 10.1038/s41409-018-0343-x) Hamilton BK, Rybicki L, Arai S, Arora M, Cutler CS, Flowers MED, et al. Association of socioeconomic status with chronic graft-versus-host disease outcomes. Biol Blood Marrow Transpl. 2018;24:393–9. (PMID: 10.1016/j.bbmt.2017.10.009) Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transpl. 2002;30:619–26. (PMID: 10.1038/sj.bmt.1703677) Boberg E, Kadri N, Winterling J, Davies LC, Bjorklund A, Msghina M, et al. Mental fatigue after allogeneic hematopoietic stem cell transplantation is associated with cognitive dysfunction, but not central nervous system inflammation. Haematologica. 2020;105:e310–e314. (PMID: 31649133727156510.3324/haematol.2019.225326) !!! INVALID CITATION !!!. Hong S, Rybicki L, Abounader DM, Bolwell BJ, Dean R, Gerds AT, et al. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma. Bone Marrow Transpl. 2016;51:1191–6. (PMID: 10.1038/bmt.2016.107) Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, et al. Patient-reported outcomes and socioeconomic status as predictors of clinical outcomes after hematopoietic stem cell transplantation: a study from the blood and marrow transplant clinical trials network 0902 trial. Biol Blood Marrow Transpl. 2016;22:2256–63. (PMID: 10.1016/j.bbmt.2016.08.016) Sun CL, Kersey JH, Francisco L, Armenian SH, Baker KS, Weisdorf DJ, et al. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study. Biol Blood Marrow Transpl. 2013;19:1073–80. (PMID: 10.1016/j.bbmt.2013.04.002) Shaw BE, Lee SJ, Horowitz MM, Wood WA, Rizzo JD, Flynn KE. Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. Bone Marrow Transpl. 2016;51:1173–9. (PMID: 10.1038/bmt.2016.113) Shaw BE, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A et al. Centralized patient‐reported outcome data collection in transplantation is feasible and clinically meaningful. Cancer. 2017;123:4687–4700. NCCN Guidelines Version 2.2021 Distress Management. The NCCN survivorship guidelines (version 3.2021). Buchbinder D, Patel SK, Casillas JN, Nugent DJ, Neudorf S, Sender LS, et al. Parent proxy assessment of sibling quality of life following pediatric hematopoietic cell transplantation. Health Qual Life Outcomes. 2019;17:162. (PMID: 31665035681963610.1186/s12955-019-1231-9) Gizli Coban O, Surer Adanir A, Ozatalay E. Post-traumatic stress disorder and health-related quality of life in the siblings of the pediatric bone marrow transplantation survivors and post-traumatic stress disorder in their mothers. Pediatr Transpl. 2017;21:e13003. (PMID: 10.1111/petr.13003) Posluszny DM, Bovbjerg DH, Syrjala KL, Agha M, Dew MA. Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies. Support Care Cancer. 2019;27:591–600. (PMID: 3002234810.1007/s00520-018-4346-3) Sannes TS, Simoneau TL, Mikulich-Gilbertson SK, Natvig CL, Brewer BW, Kilbourn K, et al. Distress and quality of life in patient and caregiver dyads facing stem cell transplant: identifying overlap and unique contributions. Support Care Cancer. 2019;27:2329–37. (PMID: 3035322910.1007/s00520-018-4496-3) Salit RB, Lee SJ, Burns LJ, Shaw BE, Majhail NS, Bhatt NS, et al. Return-to-work guidelines and programs for post-hematopoietic cell transplantation survivors: an initial survey. Biol Blood Marrow Transplant. 2020;26:1520–6. (PMID: 32360563754643210.1016/j.bbmt.2020.04.022) Salit RB, Schoeppner K, De Biase C, Mohammed J, Gonzales AL, Hashmi SK, et al. American society for transplantation and cellular therapy return to work guidance committee recommendations for health care providers who take care of hematopoietic cell transplantation patients. Transpl Cell Ther. 2022;28:822–8. (PMID: 10.1016/j.jtct.2022.09.017) Socie G, Baker KS, Bhatia S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2012;18:S139–50. (PMID: 10.1016/j.bbmt.2011.10.005) Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015–23. (PMID: 1239342710.1182/blood-2002-04-1261) Bhatia S, Armenian SH, Landier W. How I monitor long-term and late effects after blood or marrow transplantation. Blood J Am Soc Hematol. 2017;130:1302–14. Akhtari M, Bhatt VR, Tandra PK, Krishnamurthy J, Horstman H, Dreessen A, et al. Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer Biol Ther. 2013;14:1077–88. (PMID: 24025414391202910.4161/cbt.26342) Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transpl. 2011;17:771–89. (PMID: 10.1016/j.bbmt.2010.10.010) Williams L, Doucette K, Karp JE, Lai C. Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome. Bone Marrow Transpl. 2021;56:1535–49. (PMID: 10.1038/s41409-021-01214-z) Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018;74:130–6. (PMID: 30055822621991110.1016/j.leukres.2018.07.016) Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29:814–24. (PMID: 2118938710.1200/JCO.2010.28.9777) Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv. 2020;4:885–92. (PMID: 32150606706548010.1182/bloodadvances.2019001157) Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, et al. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11:63. (PMID: 33741897797988910.1038/s41408-021-00454-y) Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001. (PMID: 19264919268614610.1182/blood-2008-09-178046) Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11. (PMID: 27365460500445910.3324/haematol.2016.144428) Bilmon IA, Ashton LJ, Le Marsney RE, Dodds AJ, O’Brien TA, Wilcox L, et al. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study. Bone Marrow Transpl. 2014;49:691–8. (PMID: 10.1038/bmt.2014.13) Bomken S, Skinner R. Secondary malignant neoplasms following haematopoietic stem cell transplantation in childhood. Child (Basel). 2015;2:146–73. Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007;25:2449–54. (PMID: 1755795810.1200/JCO.2006.08.9276) Yabe M, Morio T, Tabuchi K, Tomizawa D, Hasegawa D, Ishida H, et al. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. Int J Hematol. 2021;113:134–44. (PMID: 3294937110.1007/s12185-020-02991-x) Anak S, Yalman N, Bilgen H, Sepet E, Deviren A, Gurtekin B, et al. Squamous cell carcinoma development in Fanconi anemia patients who underwent hematopoietic stem cell transplantation. Pediatr Transpl. 2020;24:e13706. (PMID: 10.1111/petr.13706) Danylesko I, Shimoni A. Second malignancies after hematopoietic stem cell transplantation. Curr Treat Options Oncol. 2018;19:9. (PMID: 2942355510.1007/s11864-018-0528-y) Ringden O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transpl. 2014;20:1777–84. (PMID: 10.1016/j.bbmt.2014.07.009) Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y, et al. Increased incidence of oral and gastrointestinal secondary cancer after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52:789–91. (PMID: 10.1038/bmt.2017.4) Knight B, Anderson L, Lerner D, Phelan R, Thakar MS. Case series: development of polyps as a late effect after total body irradiation-based hematopoietic cell transplantation in children with high-risk leukemia. J Pediatr Hematol Oncol. 2021;43:E1159–E1163. (PMID: 33828034849278610.1097/MPH.0000000000002152) Mulder RL, Kremer LC, Hudson MM, Bhatia S, Landier W, Levitt G, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2013;14:e621–29. (PMID: 24275135425760110.1016/S1470-2045(13)70303-6) Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217–23. (PMID: 24752044410093710.1200/JCO.2013.54.4601) McDonald AM, Chen Y, Wu J, Hageman L, Francisco L, Kung M, et al. Total body irradiation and risk of breast cancer after blood or marrow transplantation: a blood or marrow transplantation survivor study report. J Clin Oncol. 2020;38:2872–82. (PMID: 32673169746014910.1200/JCO.20.00231) Wang Y, Reulen RC, Kremer LCM, de Vathaire F, Haupt R, Zadravec Zaletel L, et al. Male breast cancer after childhood cancer: systematic review and analyses in the PanCareSurFup cohort. Eur J Cancer. 2022;165:27–47. (PMID: 3520297310.1016/j.ejca.2022.01.001) Moskowitz CS, Chou JF, Sklar CA, Barnea D, Ronckers CM, Friedman DN, et al. Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study. Br J Cancer. 2017;117:290–9. (PMID: 28632729552051810.1038/bjc.2017.169) Mulder RL, Hudson MM, Bhatia S, Landier W, Levitt G, Constine LS, et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the international guideline harmonization group. J Clin Oncol. 2020;38:4194–207. (PMID: 33078972772368510.1200/JCO.20.00562) Szlauer-Stefanska A, Kaminska-Winciorek G, Giebel S, Baglaj M. Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures. Adv Clin Exp Med. 2020;29:1221–30. (PMID: 3306438110.17219/acem/126739) Herr MM, Curtis RE, Tucker MA, Tecca HR, Engels EA, Cahoon EK, et al. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. J Am Acad Dermatol. 2020;83:762–72. (PMID: 3165466410.1016/j.jaad.2019.10.034) Bowers DC, Nathan PC, Constine L, Woodman C, Bhatia S, Keller K, et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. Lancet Oncol. 2013;14:e321–e328. (PMID: 23816298452292610.1016/S1470-2045(13)70107-4) Morrison CF, Pai ALH, Martsolf D. Facilitators and barriers to self-management for adolescents and young adults following a hematopoietic stem cell transplant [Formula: see text]. J Pediatr Oncol Nurs. 2018;35:36–42. (PMID: 2878630210.1177/1043454217723864) Dyer G, Gilroy N, Brown L, Hogg M, Brice L, Kabir M, et al. What they want: inclusion of blood and marrow transplantation survivor preference in the development of models of care for long-term health in Sydney, Australia. Biol Blood Marrow Transpl. 2016;22:731–43. (PMID: 10.1016/j.bbmt.2015.12.019) Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY, et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transpl. 2013;48:363–8. (PMID: 10.1038/bmt.2012.166) Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:1013–23. (PMID: 10.1038/bmt.2015.63) FACT-JACIE. FACT-JACIE International Standards for Hemopoietic Cellular Therapy Product Collection, Processing, and Administration, Seventh Edition. In, 2018. Majhail NS, Mau LW, Chitphakdithai P, Denzen EM, Joffe S, Lee SJ, et al. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transpl. 2020;55:906–17. (PMID: 10.1038/s41409-019-0748-1) Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, et al. Survey on long-term follow-up clinics for hematopoietic cell transplant survivors. Biol Blood Marrow Transpl. 2018;24:1119–24. (PMID: 10.1016/j.bbmt.2018.03.023) Kapadia M, Lehmann L, Auletta J, Beatty L, Bhatt N, Blacken R, et al. Quality improvement in hematopoietic stem cell transplant and cellular therapy: using the model for improvement to impact outcomes. Transpl Cell Ther. 2022;28:233–41. (PMID: 10.1016/j.jtct.2022.02.003) Armenian SH, Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, et al. Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transpl. 2012;47:283–90. (PMID: 10.1038/bmt.2011.60) Thaw SS, Holtan S, Cao Q, Franklin M, Paye N, Blaes A. Inadequate survivorship care after allogeneic hematopoietic cell transplantation: A retrospective chart review. F1000Research. 2018;7:1389. (PMID: 10.12688/f1000research.15633.1) Majhail NS, Murphy E, Laud P, Preussler JM, Denzen EM, Abetti B, et al. Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. Haematologica. 2019;104:1084–92. (PMID: 30514795651889610.3324/haematol.2018.203919) Syrjala KL, Yi JC, Artherholt SB, Romano JM, Crouch ML, Fiscalini AS, et al. An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation. J Cancer Surviv. 2018;12:560–70. (PMID: 29730827605455410.1007/s11764-018-0693-9) Nawas MT, Landau HJ, Sauter CS, Featherstone CA, Kenny SA, Rodriguez ES, et al. Pilot study of telehealth evaluations in patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26:e135–e137. (PMID: 10.1016/j.bbmt.2020.02.004) Chang E, Iukuridze A, Echevarria M, Teh JB, Chanson D, Ky B, et al. Feasibility and acceptability of using a telehealth platform to monitor cardiovascular risk factors in hematopoietic cell transplantation survivors at risk for cardiovascular disease. Biol Blood Marrow Transpl. 2020;26:1233–7. (PMID: 10.1016/j.bbmt.2020.02.027) Racioppi A, Dalton T, Ramalingam S, Romero K, Ren Y, Bohannon L, et al. Assessing the feasibility of a novel mhealth app in hematopoietic stem cell transplant patients. Transpl Cell Ther. 2021;27:181.e181–181.e189. (PMID: 10.1016/j.jtct.2020.10.017) Leppla L, Schmid A, Valenta S, Mielke J, Beckmann S, Ribaut J, et al. Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth-the SMILe study. Support Care Cancer. 2021;29:8045–57. (PMID: 34224016855034910.1007/s00520-021-06328-0) Syrjala KL, Crouch ML, Leisenring WM, Flowers MED, Artherholt SB, Fiscalini AS, et al. Engagement with INSPIRE, an online program for hematopoietic cell transplantation survivors. Biol Blood Marrow Transpl. 2018;24:1692–8. (PMID: 10.1016/j.bbmt.2018.05.004) Leppla L, Mielke J, Kunze M, Mauthner O, Teynor A, Valenta S, et al. Clinicians and patients perspectives on follow-up care and eHealth support after allogeneic hematopoietic stem cell transplantation: A mixed-methods contextual analysis as part of the SMILe study. Eur J Oncol Nurs. 2020;45:101723. (PMID: 3206236210.1016/j.ejon.2020.101723) Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40:17–65. (PMID: 3018416010.1210/er.2018-00006) Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021;138:942–7. (PMID: 3411513610.1182/blood.2021011488) Tucci F, Galimberti S, Naldini L, Valsecchi MG, Aiuti A. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat Commun. 2022;13:1315. (PMID: 35288539892123410.1038/s41467-022-28762-2) Jarisch A, Salzmann-Manrique E, Cario H, Grosse R, Soerensen J, Fischer R, et al. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation. Eur J Haematol. 2018;101:791–7. (PMID: 3018757110.1111/ejh.13169) Pepe A, Pistoia L, Gamberini MR, Cuccia L, Peluso A, Messina G, et al. The close link of pancreatic iron with glucose metabolism and with cardiac complications in thalassemia major: a large, multicenter observational study. Diabetes Care. 2020;43:2830–9. (PMID: 3288770810.2337/dc20-0908) Bardi E, Mulder RL, van Dalen EC, Bhatt NS, Ruble KA, Burgis J, et al. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. Cancer Treat Rev. 2021;100:102296. (PMID: 3457137810.1016/j.ctrv.2021.102296) Aboobacker FN, Dixit G, Lakshmi KM, Korula A, Abraham A, George B, et al. Outcome of iron reduction therapy in ex-thalassemics. PLoS One. 2021;16:e0238793. (PMID: 33481797782227010.1371/journal.pone.0238793) Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–6. (PMID: 25605844488137210.1200/JCO.2014.59.7351) Group IMW. IMWG guidelines for the prevention of thalidomide and lenalidomide-associated thrombosis in myeloma. In. Carpenter PA, Englund JA. Commentary: is immune recovery-based post-transplantation vaccination in children better than time-based revaccination? Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther. 2021;27:281–3. Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: iia. the 2020 clinical implementation and early diagnosis working group report. Transpl Cell Ther. 2021;27:545–57. (PMID: 10.1016/j.jtct.2021.03.033) Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9. (PMID: 21263156306231910.1182/blood-2010-08-302109) Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transpl. 2011;46:1283–95. (PMID: 10.1038/bmt.2011.35) Cheng GS, Selwa KE, Hatt C, Ram S, Fortuna AB, Guerriero M, et al. Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Am J Transpl. 2020;20:2198–205. (PMID: 10.1111/ajt.15814) Rayment JH, Sandoval RA, Roden JP, Schultz KR. Multiple breath washout testing to identify pulmonary chronic graft versus host disease in children after hematopoietic stem. Cell Transplant Transpl Cell Ther. 2022;28:328.e321–328.e327. Jamani K, He Q, Liu Y, Davis C, Hubbard J, Schoch G, et al. Early post-transplantation spirometry is associated with the development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26:943–8. (PMID: 10.1016/j.bbmt.2019.12.002) Turner J, He Q, Baker K, Chung L, Lazarevic-Fogelquist A, Bethune D, et al. Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. Transpl Cell Ther. 2021;27:616.e611–616.e616. (PMID: 10.1016/j.jtct.2021.03.024) Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, et al. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13:1932–9. (PMID: 27513368512247910.1513/AnnalsATS.201604-262OC) Dietz AC, Mehta PA, Vlachos A, Savage SA, Bresters D, Tolar J, et al. Current knowledge and priorities for future research in late effects after hematopoietic cell transplantation for inherited bone marrow failure syndromes: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2017;23:726–35. (PMID: 10.1016/j.bbmt.2017.01.075) Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42:1409–26. (PMID: 2055906410.1249/MSS.0b013e3181e0c112) DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, et al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transpl. 2017;52:173–82. (PMID: 10.1038/bmt.2016.203) Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57. (PMID: 3237057210.1161/HYPERTENSIONAHA.120.15026) Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:e177–e232. (PMID: 30894318768556510.1016/j.jacc.2019.03.010) Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5:864–71. (PMID: 30703192649023210.1001/jamaoncol.2018.6634) Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16:e123–136. (PMID: 25752563448545810.1016/S1470-2045(14)70409-7) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Survivorship. In. Version 1.2022 ed, 2022. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99. (PMID: 2940532910.1002/hep.29800) Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–29. (PMID: 2593555110.1093/cid/civ344) Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review. Viruses. 2019;11. AASLD/IDSA/IASeUSA. Recommendations for testing, managing, and treating hepatitis C. In. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.). 2011;53:1020. (PMID: 2137466610.1002/hep.24199) Chemaitilly W, Sklar CA. Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab Clin North Am. 2007;36:983–98. (PMID: 1798393210.1016/j.ecl.2007.07.002) Salooja N, Shoham Z, Dalle JH. Endocrine Disorders, Fertility and Sexual Health. In: th, Carreras E, Dufour C, Mohty M, Kroger N (eds). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer Copyright 2019, EBMT and the Author(s). Cham (CH), 2019, pp 421-7. Syrjala KL, Kurland BF, Abrams JR, Sanders JE, Heiman JR. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood. 2008;111:989–96. (PMID: 17878404221474210.1182/blood-2007-06-096594) El-Jawahri A, Fishman SR, Vanderklish J, Dizon DS, Pensak N, Traeger L, et al. Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. Cancer. 2018;124:2438–46. (PMID: 2953749110.1002/cncr.31333) Brotto LA, Yule M, Breckon E. Psychological interventions for the sexual sequelae of cancer: a review of the literature. J Cancer Surviv. 2010;4:346–60. (PMID: 2060218810.1007/s11764-010-0132-z) Meacham LR, Burns K, Orwig KE, Levine J. Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer: the pediatric initiative network risk stratification system. J Adolesc Young- Adult Oncol. 2020;9:662–6. (PMID: 3245657010.1089/jayao.2020.0012) Bachrach LK, Gordon CM, Section On E. Bone densitometry in children and adolescents. Pediatrics 2016;138. Lewiecki EM, Laster AJ. Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab. 2006;91:4215–22. (PMID: 1694044710.1210/jc.2006-1178) Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, et al. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos. 2018;13:1–8. (PMID: 2961957610.1007/s11657-018-0453-5) Pundole X, Cheema HI, Petitto GS, Lopez-Olivo MA, Suarez-Almazor ME, Lu H. Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis. Bone Marrow Transpl. 2017;52:663–70. (PMID: 10.1038/bmt.2016.312) Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, et al. Role of bone-modifying agents in multiple myeloma: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2018;36:812–8. (PMID: 2934183110.1200/JCO.2017.76.6402) Guffon N, Pettazzoni M, Pangaud N, Garin C, Lina-Granade G, Plault C, et al. Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT). Orphanet J Rare Dis. 2021;16:60. (PMID: 33517895784759110.1186/s13023-020-01644-w) Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med. 2018;20:1423–9. (PMID: 29517765612922910.1038/gim.2018.29) Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Seminars in hematology. Elsevier, 2012. Inamoto Y, Martin PJ, Flowers ME, Lee SJ, Carpenter PA, Warren EH, et al. Genetic risk factors for sclerotic graft-versus-host disease. Blood. 2016;128:1516–24. (PMID: 27313329502590110.1182/blood-2016-05-715342) Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood. 2011;118:4250–7. (PMID: 21791415320474110.1182/blood-2011-04-350249) Kuo CY, Garabedian E, Puck J, Cowan MJ, Sullivan KE, Buckley RH et al. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. J Clin Immunol. 2020; 1124-31. Bonfim C. Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. Hematol Am Soc Hematol Educ Program. 2020;2020:107–114. (PMID: 10.1182/hematology.2020000095) Baker KS, Leisenring WM, Goodman PJ, Ermoian RP, Flowers ME, Schoch G, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood, The Journal of the American Society of Hematology 2019;133:2790–2799. (PMID: 30992266659837910.1182/blood.2018874115) NetworkNCC. Breast Cancer Risk Reduction. In: NCCN Clinical Practice Guidelines in Oncology: NCCN, 2021. Bozzuto LM. Breast Cancer Risk Reduction: who, why and what? Best Pract Res Clin Obstetr Gynaecol. 2021. Clement SC, Kremer LCM, Verburg FA, Simmons JH, Goldfarb M, Peeters RP, et al. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2018;63:28–39. (PMID: 2920244510.1016/j.ctrv.2017.11.005) Meignin V, Gluckman E, Gambaraelli D, Devergie A, Ramee MP, Janin A, et al. Meningioma in long-term survivors after allogeneic bone marrow transplantation. Bone Marrow Transpl. 1998;22:723–4. (PMID: 10.1038/sj.bmt.1701407) Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013;31:2469–76. (PMID: 23690411380713910.1200/JCO.2012.47.0500) Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2007;44:1–9. (PMID: 1682543110.1136/jmg.2006.043257) Myers K, Davies SM, Harris RE, Spunt SL, Smolarek T, Zimmerman S, et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr Blood Cancer. 2012;58:462–5. (PMID: 2154801410.1002/pbc.23168) Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162–4. (PMID: 1720067110.1038/ng1947) Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, Satagopan J, et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood. 2004;103:3226–9. (PMID: 1507070710.1182/blood-2003-09-3138) Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, et al. Cancer screening recommendations for individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017;23:e38–e45. (PMID: 2857226610.1158/1078-0432.CCR-17-0408)
معلومات مُعتمدة:	2KL2TR002547 U.S. Department of Health & Human Services \| NIH \| National Center for Advancing Translational Sciences (NCATS); R01CA215134 U.S. Department of Health & Human Services \| NIH \| National Cancer Institute (NCI)
تواريخ الأحداث:	Date Created: 20240227 Date Completed: 20240607 Latest Revision: 20240621
رمز التحديث:	20240622
DOI:	10.1038/s41409-023-02190-2
PMID:	38413823
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1476-5365
DOI:	10.1038/s41409-023-02190-2